

## Immunosyn Corporation (OTC BB: IMYN)



Immunosyn Corporation, founded in 2006 and headquartered in La Jolla, CA, is a development stage marketing and distribution company with a pipeline of innovative therapeutics focusing on chronic auto-immune, infectious disease and neurological disorders.

The company has exclusive worldwide rights acquired from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound derived from mammalian cells that was developed through extensive Biological Response Modifiers (BRMs) research conducted by leading medical research institutions in the U.S. The license encompasses the entire patent-pending SF-1019 platform technology for auto-immune, neurological and demyelinating conditions, along with any possible future application variants. Research suggests that SF-1019, which has been widely evaluated in a number of veterinary treatments and animal studies relating to human disease, has the potential to affect a number of clinical conditions, including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS), neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS), also known as Complex Regional Pain Syndrome (CRPS). SF-1019 is administered by a medical professional as a subcutaneous injection. Argyll Biotechnologies, LLC, responsible for manufacturing, regulatory and other business functions per the license agreement, has initiated the process of clinical trial approval of SF-1019 relating to CIDP and RSDS with the Food and Drug Administration (FDA), as well as relating to DU and other wound healing with the European Medicines Agency (EMA). The company also has long term plans to bring to market other biopharmaceuticals products that have been previously developed for veterinary use.

CURRENT PRICE: \$2.75  
 52-WEEK RANGE: \$1.40 - \$6.90  
 AVG DAILY VOLUME (90-DAY): 27,893  
 OUTSTANDING SHARES: 272.0 million  
**MARKET CAPITALIZATION: \$748.0 million**

### INCOME STATEMENT HIGHLIGHTS

REVENUE: Nil  
 NET INCOME: (\$119.6 thousand)  
 EPS (Diluted): (\$0.00)

All figures three months ended September 30, 2007

### BALANCE SHEET HIGHLIGHTS

CASH & EQUIVALENTS: \$11.1 thousand  
 WORKING CAPITAL: (\$497.6 thousand)  
 TOTAL ASSETS: \$419.3 thousand  
 TOTAL DEBT: \$488.1 thousand  
 NET WORTH: \$89.9 thousand

All figures as of September 30, 2007

### RECENT NEWS HEADLINES

Wed, Nov 28, 2007

Immunosyn announced that Biozyme Laboratories Limited, a UK based medical company, has received approval from the Medicines and Healthcare products Regulatory Agency, which functions in the United Kingdom on behalf of the European Medicines Agency (EMA), to import base material and manufacture SF-1019 for human use in clinical trials.

Thu, Nov 8, 2007

Immunosyn released the SF-1019 Compassionate Provisional Studies Summary (CFR 312.36) describing the results of limited feasibility clinical studies conducted by The Institute of Biologic Research on several progressive neurological auto-immune and inflammatory conditions for which there is no satisfactory form of therapy, showing specific measurable improvements in neurological scores assessing the levels of tremor, numbness, motor strength, walking, balance, speech, pain and coordination in patients., as well as stable comprehensive metabolic profiles and blood counts before and after injections.

### HEADQUARTERS

**Immunosyn Corporation**  
 4225 Executive Square  
 La Jolla, CA 92037  
 Phone: 858-200-2320  
 Web Site: [www.immunosyn.com](http://www.immunosyn.com)



The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to the accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. For complete disclaimer information, the reader is hereby referred to the Disclaimer Page of the Flaherty Financial News / WallStreet Research Small Cap Conference Book or the [www.WallStreetResearch.org](http://www.WallStreetResearch.org) website.